Cantor Fitzgerald initiated coverage of HCA Healthcare with an Overweight rating and $304 price target. Contract negotiating power could be key to margin expansion at this part of the healthcare cycle, which could benefit the company given its position as market-share leader in the acute hospitals space, the analyst tells investors in a research note. Cantor further cites HCA’s well-capitalized balance sheet that should help it achieve market-share gains in 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HCA: